BRPI0416085A - álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos - Google Patents

álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos

Info

Publication number
BRPI0416085A
BRPI0416085A BRPI0416085-1A BRPI0416085A BRPI0416085A BR PI0416085 A BRPI0416085 A BR PI0416085A BR PI0416085 A BRPI0416085 A BR PI0416085A BR PI0416085 A BRPI0416085 A BR PI0416085A
Authority
BR
Brazil
Prior art keywords
cytotoxic agents
corresponding phosphates
target
nitrophenylaziridine
alcohols
Prior art date
Application number
BRPI0416085-1A
Other languages
English (en)
Portuguese (pt)
Inventor
William Alexander Denny
Graham John Atwell
Shangjin Yang
William Robert Wilson
Adam Vorn Patterson
Nuala Ann Helsby
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NZ529249A external-priority patent/NZ529249A/en
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of BRPI0416085A publication Critical patent/BRPI0416085A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66Methanesulfonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0416085-1A 2003-10-31 2004-10-29 álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos BRPI0416085A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ529249A NZ529249A (en) 2003-10-31 2003-10-31 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic
NZ53561804 2004-09-28
PCT/NZ2004/000275 WO2005042471A1 (en) 2003-10-31 2004-10-29 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents

Publications (1)

Publication Number Publication Date
BRPI0416085A true BRPI0416085A (pt) 2007-01-02

Family

ID=34555019

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416085-1A BRPI0416085A (pt) 2003-10-31 2004-10-29 álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos

Country Status (10)

Country Link
US (2) US7629332B2 (https=)
EP (1) EP1680394A4 (https=)
JP (1) JP4760712B2 (https=)
KR (1) KR101167335B1 (https=)
AU (1) AU2004285831B2 (https=)
BR (1) BRPI0416085A (https=)
CA (1) CA2544335A1 (https=)
IL (1) IL175000A0 (https=)
RU (1) RU2372324C2 (https=)
WO (1) WO2005042471A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629332B2 (en) * 2003-10-31 2009-12-08 Auckland Uniservices Limited Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
NZ549659A (en) * 2006-09-04 2008-12-24 Auckland Uniservices Ltd Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom
WO2008033039A1 (en) * 2006-09-11 2008-03-20 Adam Vorn Patterson Cancer treatment
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
WO2008033041A1 (en) * 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
WO2009140553A2 (en) * 2008-05-15 2009-11-19 Threshold Pharmaceuticals, Inc. Hypoxia activated drugs of nitrogen mustard alkylators
WO2010044685A1 (en) * 2008-10-17 2010-04-22 Auckland Uniservices Limited Nitrophenyl mustard alcohols, their corresponding phosphates and their use as targeted cytotoxic agents
JP5765634B2 (ja) 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ, インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
WO2012009288A2 (en) 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
CN104039328B (zh) * 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
WO2014007650A1 (en) * 2011-12-23 2014-01-09 Auckland Uniservices Limited Compounds and methods for selective imaging and/or ablation
US10202408B2 (en) 2012-08-23 2019-02-12 Health Innovation Ventures B.V. Prodrugs and methods of use thereof
CN105051004B (zh) * 2012-08-23 2017-12-05 健康创新企业私人有限责任公司 新型前体药物及其使用方法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20160158253A1 (en) 2013-07-26 2016-06-09 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
US10348685B2 (en) * 2016-04-29 2019-07-09 Nicira, Inc. Priority allocation for distributed service rules
CN108571241B (zh) * 2017-03-14 2021-08-17 福特环球技术公司 用于推按式闩锁类型车辆抽屉的惯性锁系统
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
WO2019190331A1 (en) * 2018-03-29 2019-10-03 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
WO2019229195A1 (en) * 2018-05-30 2019-12-05 Convert Pharmaceuticals S.A. Prodrugs and medical uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ240785A (en) * 1991-11-28 1995-08-28 Cancer Res Campaign Tech Substituted nitro aniline derivatives and medicaments
GB9819472D0 (en) * 1998-09-07 1998-10-28 Cancer Soc Auckland Div Nz Inc Novel nitrophenylaziridine compounds and their use as prodrugs
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
NZ521851A (en) * 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
US7629332B2 (en) * 2003-10-31 2009-12-08 Auckland Uniservices Limited Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents

Also Published As

Publication number Publication date
US20070032455A1 (en) 2007-02-08
IL175000A0 (en) 2006-08-20
EP1680394A1 (en) 2006-07-19
RU2372324C2 (ru) 2009-11-10
JP4760712B2 (ja) 2011-08-31
JP2007509928A (ja) 2007-04-19
US7629332B2 (en) 2009-12-08
AU2004285831B2 (en) 2011-09-15
AU2004285831A1 (en) 2005-05-12
US20100010094A1 (en) 2010-01-14
KR101167335B1 (ko) 2012-07-19
CA2544335A1 (en) 2005-05-12
RU2006118785A (ru) 2007-12-10
WO2005042471A1 (en) 2005-05-12
KR20070006677A (ko) 2007-01-11
EP1680394A4 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
BRPI0416085A (pt) álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos
Yang et al. Enzyme-mediated hydrolytic activation of prodrugs
DE69535916D1 (de) Oberflächenlokalisierte Expression von Enzymen in gengesteuerter Prodrugtherapie
EA200702239A1 (ru) Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
IL158623A0 (en) Subcellular targeting of therapeutic proteins
IL207446A0 (en) Acid alpha-glucosidase and fragments thereof
AU2001288025A1 (en) Peptide conjugated anti-cancer prodrugs
BR0206648A (pt) Inserto de corte, e, ferramenta de corte
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
TW200514252A (en) Self-aligned planar double-gate process by self-aligned oxidation
MY140975A (en) Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
WO2024073723A3 (en) Anti-cd122 antibodies and uses thereof
YU61398A (sh) Derivati tiazola
TR200201089T2 (tr) Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2004053054A3 (en) Nk cell receptor conjugates for treating malignancies
ATE332377T1 (de) P450 / acetaminophen gdept zur krebsbehandlung
Blakey et al. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease
WO2022020473A3 (en) Disruption of cd28-sialoside ligand complexes to enhance t cell activation
BR9610050A (pt) Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
WO2009006541A3 (en) Proteinases destroy cancer tumor's solid structure and kill cancer cells locally
WO2006113889A3 (en) Compositions and methods for modulating interleukin-10
EP1161262A4 (en) COLLIGIN / HsP47 ISOLATED ON THE SURFACE OF CARCINOMA CELLS
WO2005010911A3 (en) Longitudinal cathode expansion in an ion source

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014.